BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5803/ 1
- Ask / Lots0.6600/ 7
- Open / Previous Close0.6000 / 0.5900
- Day Range
- 52 Week Range
- Volume271,799
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 4046 | 0.6001 |
| 09:34 ET | 400 | 0.59 |
| 09:36 ET | 100 | 0.5975 |
| 09:41 ET | 500 | 0.6048 |
| 09:45 ET | 3691 | 0.5975 |
| 09:50 ET | 800 | 0.59 |
| 09:57 ET | 3300 | 0.59 |
| 10:03 ET | 700 | 0.6027 |
| 10:08 ET | 7300 | 0.59 |
| 10:10 ET | 2400 | 0.5921 |
| 10:12 ET | 1800 | 0.5916 |
| 10:19 ET | 200 | 0.6007 |
| 10:21 ET | 2000 | 0.5916 |
| 10:24 ET | 500 | 0.6032 |
| 10:28 ET | 2050 | 0.6 |
| 10:32 ET | 3500 | 0.6 |
| 10:33 ET | 1100 | 0.6 |
| 10:35 ET | 1900 | 0.59 |
| 10:44 ET | 652 | 0.59505 |
| 10:53 ET | 11011 | 0.59 |
| 10:55 ET | 1000 | 0.5901 |
| 11:00 ET | 100 | 0.6 |
| 11:04 ET | 1000 | 0.5902 |
| 11:13 ET | 600 | 0.593 |
| 11:22 ET | 5797 | 0.594 |
| 11:24 ET | 400 | 0.6 |
| 11:27 ET | 250 | 0.6 |
| 11:38 ET | 800 | 0.6 |
| 11:45 ET | 2600 | 0.5999 |
| 11:47 ET | 5902 | 0.595049 |
| 11:49 ET | 2600 | 0.595049 |
| 11:51 ET | 5900 | 0.6 |
| 11:54 ET | 6800 | 0.590101 |
| 11:56 ET | 5000 | 0.5999 |
| 11:58 ET | 8500 | 0.5998 |
| 12:00 ET | 2500 | 0.5999 |
| 12:09 ET | 1100 | 0.5951 |
| 12:21 ET | 3494 | 0.59 |
| 12:32 ET | 49740 | 0.5807 |
| 12:36 ET | 1105 | 0.5997 |
| 12:39 ET | 1813 | 0.5997 |
| 12:41 ET | 3000 | 0.58785 |
| 12:43 ET | 6631 | 0.58 |
| 12:59 ET | 775 | 0.5979 |
| 01:06 ET | 400 | 0.5963 |
| 01:08 ET | 2600 | 0.5895 |
| 01:32 ET | 100 | 0.5833 |
| 01:39 ET | 10449 | 0.59094 |
| 02:06 ET | 2000 | 0.5761 |
| 02:08 ET | 5000 | 0.5762 |
| 02:15 ET | 12370 | 0.5801 |
| 02:24 ET | 18130 | 0.5855 |
| 02:26 ET | 800 | 0.5855 |
| 02:27 ET | 1203 | 0.594049 |
| 02:29 ET | 1000 | 0.597999 |
| 02:33 ET | 15826 | 0.595 |
| 02:36 ET | 486 | 0.5905 |
| 02:44 ET | 168 | 0.58465 |
| 02:51 ET | 2700 | 0.5803 |
| 02:54 ET | 100 | 0.5824 |
| 02:58 ET | 2436 | 0.5947 |
| 03:05 ET | 4842 | 0.593 |
| 03:07 ET | 100 | 0.5866 |
| 03:09 ET | 200 | 0.5864 |
| 03:16 ET | 200 | 0.5924 |
| 03:18 ET | 2000 | 0.59 |
| 03:23 ET | 510 | 0.59 |
| 03:25 ET | 1400 | 0.59 |
| 03:32 ET | 200 | 0.595 |
| 03:34 ET | 1231 | 0.59144 |
| 03:41 ET | 100 | 0.5938 |
| 03:43 ET | 3450 | 0.598 |
| 03:50 ET | 6333 | 0.5851 |
| 03:54 ET | 400 | 0.59 |
| 03:56 ET | 100 | 0.59 |
| 03:59 ET | 2812 | 0.59 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 51.6M | -0.8x | --- |
Dyadic International Inc | 51.5M | -6.5x | --- |
LAVA Therapeutics NV | 48.9M | -1.7x | --- |
Lipocine Inc | 48.0M | -5.3x | --- |
Cue Biopharma Inc | 65.7M | -1.3x | --- |
Kezar Life Sciences Inc | 46.8M | -0.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $51.6M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
